TGCT

Pexidartinib Yields Tumor Regression in Patients with TGCT

11/22/2021

Pexidartinib demonstrated durable tumor regression, with manageable safety, in patients with TGCT.

Pexidartinib demonstrated...

11/22/2021

Oncology

Test Your Knowledge

Quiz: Does Vimseltinib Exhibit Antitumor Activity in TGCT?

09/30/2021

True or false: Results from a study presented at the 2021 ESMO Congress showed Vimseltinib did not yield promising antitumor activity in tenosynovial giant cell tumor (TGCT).

True or false: Results from a...

09/30/2021

Oncology

Vimseltinib Demonstrates Promising Antitumor Activity in TGCT

09/17/2021

According to data presented at the 2021 Virtual ESMO Congress, vimseltinib was well tolerated and demonstrated antitumor activity in patients with TGCT.

According to data presented at...

09/17/2021

Oncology